Evidence map›Paper›PMID 41189580›Full record

ArticleERJ open research2025

Efficacy of elexacaftor/tezacaftor/ivacaftor in non-cystic fibrosis bronchiectasis patients with a single pathogenic

Lena Papadakis, Isabel Neuringer, Hang Lee, Anne O'Donnell, Julia Zweifach, Brenden Lawton, Leonard Sicilian, Rocio Hurtado, Tayler Stander, Lindsay Bringhurst and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lena PapadakisPediatric Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Isabel NeuringerAdult Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Hang LeeMGH Center for Biostatistics, Massachusetts General Hospital, Boston, MA, USA.
Anne O'DonnellDivision of Pulmonary, Critical Care and Sleep Medicine, Georgetown University, Washington, DC, USA.
Julia ZweifachPediatric Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Brenden LawtonPediatric Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Leonard SicilianAdult Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Rocio HurtadoDivision of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Tayler StanderAdult Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Lindsay BringhurstAdult Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.
Christopher RichardsAdult Cystic Fibrosis Center, Massachusetts General Hospital, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: It has previously been established that there is an increased incidence of mutations in the cystic fibrosis transmembrane regulator ( Methods: We assembled a retrospective cohort of patients (n=12) with a single Results: Improvements in pulmonary symptoms were observed in all 12 patients (100%), and 11 patients (91.6%) expressed improvement in quality of life. Mean % predicted forced expiratory volume in 1 s improved significantly from 69.3% to 75.0% (p Conclusion: Amongst patients presenting with NCFB and an amenable

Identifiers

PMID41189580
PMCPMC12581160

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.